Medication Discontinuation and Reinitiation Among Medicare Part D Beneficiaries Taking Costly Medications

Medication Discontinuation and Reinitiation Among Medicare Part D Beneficiaries Taking Costly Medications

Published: Sep 13, 2011
Publisher: American Journal of Pharmacy Benefits, vol. 3, no. 5
Download
Authors

Margaret Colby

Dominick Esposito

Seth Goldfarb

Daniel E. Ball

Vivian Herrera

Susan B. Garavaglia

Eric S. Meadows

Martin D. Marciniak

This study looked at the impact of Medicare Part D coverage gaps by examining drug discontinuation and reinitiation among Medicare beneficiaries using medications for cancer or rheumatoid arthritis. The study found that patients in the arthritis or cancer groups—28 and 21 percent, respectively—discontinued medications for these conditions in 2006; about three-fourths reinitiated therapy in the first 90 days of 2007. Although medication discontinuation is often temporary, the effect is complex. Some patients might discontinue before reaching the coverage gap to avoid out-of-pocket costs. For those who spend into or through the coverage gap before discontinuing, cumulative out-of-pocket expenditures might be too high to resume treatment the following year.

How do you apply evidence?

Take our quick four-question survey to help us curate evidence and insights that serve you.

Take our survey